Development of Medical Countermeasures to Middle East Respiratory Syndrome Coronavirus
Identifieur interne : 000074 ( Pmc/Curation ); précédent : 000073; suivant : 000075Development of Medical Countermeasures to Middle East Respiratory Syndrome Coronavirus
Auteurs : Timothy M. Uyeki ; Karl J. Erlandson ; George Korch ; Michael O Ara ; Michael Wathen ; Jean Hu-Primmer ; Sally Hojvat ; Erik J. Stemmy ; Armen DonabedianSource :
- Emerging Infectious Diseases [ 1080-6040 ] ; 2016.
Abstract
Preclinical development of and research on potential Middle East respiratory syndrome coronavirus (MERS-CoV) medical countermeasures remain preliminary; advancements are needed before most countermeasures are ready to be tested in human clinical trials. Research priorities include standardization of animal models and virus stocks for studying disease pathogenesis and efficacy of medical countermeasures; development of MERS-CoV diagnostics; improved access to nonhuman primates to support preclinical research; studies to better understand and control MERS-CoV disease, including vaccination studies in camels; and development of a standardized clinical trial protocol. Partnering with clinical trial networks in affected countries to evaluate safety and efficacy of investigational therapeutics will strengthen efforts to identify successful medical countermeasures.
Url:
DOI: 10.3201/eid2207.160022
PubMed: 27191188
PubMed Central: 4918159
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000074
Links to Exploration step
PMC:4918159Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of Medical Countermeasures to Middle East Respiratory Syndrome Coronavirus</title><author><name sortKey="Uyeki, Timothy M" sort="Uyeki, Timothy M" uniqKey="Uyeki T" first="Timothy M." last="Uyeki">Timothy M. Uyeki</name></author><author><name sortKey="Erlandson, Karl J" sort="Erlandson, Karl J" uniqKey="Erlandson K" first="Karl J." last="Erlandson">Karl J. Erlandson</name></author><author><name sortKey="Korch, George" sort="Korch, George" uniqKey="Korch G" first="George" last="Korch">George Korch</name></author><author><name sortKey="O Ara, Michael" sort="O Ara, Michael" uniqKey="O Ara M" first="Michael" last="O Ara">Michael O Ara</name></author><author><name sortKey="Wathen, Michael" sort="Wathen, Michael" uniqKey="Wathen M" first="Michael" last="Wathen">Michael Wathen</name></author><author><name sortKey="Hu Primmer, Jean" sort="Hu Primmer, Jean" uniqKey="Hu Primmer J" first="Jean" last="Hu-Primmer">Jean Hu-Primmer</name></author><author><name sortKey="Hojvat, Sally" sort="Hojvat, Sally" uniqKey="Hojvat S" first="Sally" last="Hojvat">Sally Hojvat</name></author><author><name sortKey="Stemmy, Erik J" sort="Stemmy, Erik J" uniqKey="Stemmy E" first="Erik J." last="Stemmy">Erik J. Stemmy</name></author><author><name sortKey="Donabedian, Armen" sort="Donabedian, Armen" uniqKey="Donabedian A" first="Armen" last="Donabedian">Armen Donabedian</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">27191188</idno><idno type="pmc">4918159</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918159</idno><idno type="RBID">PMC:4918159</idno><idno type="doi">10.3201/eid2207.160022</idno><date when="2016">2016</date><idno type="wicri:Area/Pmc/Corpus">000074</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000074</idno><idno type="wicri:Area/Pmc/Curation">000074</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000074</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Development of Medical Countermeasures to Middle East Respiratory Syndrome Coronavirus</title><author><name sortKey="Uyeki, Timothy M" sort="Uyeki, Timothy M" uniqKey="Uyeki T" first="Timothy M." last="Uyeki">Timothy M. Uyeki</name></author><author><name sortKey="Erlandson, Karl J" sort="Erlandson, Karl J" uniqKey="Erlandson K" first="Karl J." last="Erlandson">Karl J. Erlandson</name></author><author><name sortKey="Korch, George" sort="Korch, George" uniqKey="Korch G" first="George" last="Korch">George Korch</name></author><author><name sortKey="O Ara, Michael" sort="O Ara, Michael" uniqKey="O Ara M" first="Michael" last="O Ara">Michael O Ara</name></author><author><name sortKey="Wathen, Michael" sort="Wathen, Michael" uniqKey="Wathen M" first="Michael" last="Wathen">Michael Wathen</name></author><author><name sortKey="Hu Primmer, Jean" sort="Hu Primmer, Jean" uniqKey="Hu Primmer J" first="Jean" last="Hu-Primmer">Jean Hu-Primmer</name></author><author><name sortKey="Hojvat, Sally" sort="Hojvat, Sally" uniqKey="Hojvat S" first="Sally" last="Hojvat">Sally Hojvat</name></author><author><name sortKey="Stemmy, Erik J" sort="Stemmy, Erik J" uniqKey="Stemmy E" first="Erik J." last="Stemmy">Erik J. Stemmy</name></author><author><name sortKey="Donabedian, Armen" sort="Donabedian, Armen" uniqKey="Donabedian A" first="Armen" last="Donabedian">Armen Donabedian</name></author></analytic><series><title level="j">Emerging Infectious Diseases</title><idno type="ISSN">1080-6040</idno><idno type="eISSN">1080-6059</idno><imprint><date when="2016">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Preclinical development of and research on potential Middle East respiratory syndrome coronavirus (MERS-CoV) medical countermeasures remain preliminary; advancements are needed before most countermeasures are ready to be tested in human clinical trials. Research priorities include standardization of animal models and virus stocks for studying disease pathogenesis and efficacy of medical countermeasures; development of MERS-CoV diagnostics; improved access to nonhuman primates to support preclinical research; studies to better understand and control MERS-CoV disease, including vaccination studies in camels; and development of a standardized clinical trial protocol. Partnering with clinical trial networks in affected countries to evaluate safety and efficacy of investigational therapeutics will strengthen efforts to identify successful medical countermeasures.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><pmc article-type="meeting-report"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Emerging Infect. Dis</journal-id><journal-id journal-id-type="publisher-id">EID</journal-id><journal-title-group><journal-title>Emerging Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">1080-6040</issn><issn pub-type="epub">1080-6059</issn><publisher><publisher-name>Centers for Disease Control and Prevention</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27191188</article-id><article-id pub-id-type="pmc">4918159</article-id><article-id pub-id-type="publisher-id">16-0022</article-id><article-id pub-id-type="doi">10.3201/eid2207.160022</article-id><article-categories><subj-group subj-group-type="heading"><subject>Online Report</subject></subj-group><subj-group subj-group-type="article-type"><subject>Online Report</subject></subj-group><subj-group subj-group-type="TOC-title"><subject>Development of Medical Countermeasures to Middle East Respiratory Syndrome Coronavirus</subject></subj-group></article-categories><title-group><article-title>Development of Medical Countermeasures to Middle East Respiratory Syndrome Coronavirus</article-title><alt-title alt-title-type="running-head">Medical Countermeasures to MERS-CoV</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Uyeki</surname><given-names>Timothy M.</given-names></name><xref ref-type="fn" rid="FN1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Erlandson</surname><given-names>Karl J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Korch</surname><given-names>George</given-names></name></contrib><contrib contrib-type="author"><name><surname>O’Hara</surname><given-names>Michael</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wathen</surname><given-names>Michael</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hu-Primmer</surname><given-names>Jean</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hojvat</surname><given-names>Sally</given-names></name></contrib><contrib contrib-type="author"><name><surname>Stemmy</surname><given-names>Erik J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Donabedian</surname><given-names>Armen</given-names></name><xref ref-type="fn" rid="FN1"><sup>1</sup></xref></contrib><aff id="aff1">Centers for Disease Control and Prevention, Atlanta, Georgia, USA (T.M. Uyeki);</aff><aff id="aff2">Office of the Assistant Secretary of Preparedness and Response, Washington, DC, USA (K.J. Erlandson, G. Korch, M. O’Hara, M. Wathen, J. Hu-Primmer, A. Donabedian);</aff><aff id="aff3">Food and Drug Administration, Silver Spring, Maryland, USA (S. Hojvat);</aff><aff id="aff4">National Institutes of Health, Rockville, Maryland, USA (E.J. Stemmy)</aff></contrib-group><author-notes><corresp id="cor1">Address for correspondence: Timothy M. Uyeki, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop A20, Atlanta, GA 30329-4027; email: <email xlink:href="tuyeki@cdc.gov">tuyeki@cdc.gov</email></corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2016</year></pub-date><volume>22</volume><issue>7</issue><elocation-id>e160022</elocation-id><abstract><p>Preclinical development of and research on potential Middle East respiratory syndrome coronavirus (MERS-CoV) medical countermeasures remain preliminary; advancements are needed before most countermeasures are ready to be tested in human clinical trials. Research priorities include standardization of animal models and virus stocks for studying disease pathogenesis and efficacy of medical countermeasures; development of MERS-CoV diagnostics; improved access to nonhuman primates to support preclinical research; studies to better understand and control MERS-CoV disease, including vaccination studies in camels; and development of a standardized clinical trial protocol. Partnering with clinical trial networks in affected countries to evaluate safety and efficacy of investigational therapeutics will strengthen efforts to identify successful medical countermeasures.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords: </title><kwd>Middle East respiratory syndrome coronavirus</kwd><kwd>MERS-CoV</kwd><kwd>medical countermeasures</kwd><kwd>animal models</kwd><kwd>non-human primates</kwd><kwd>nonhuman primates</kwd><kwd>diagnostics</kwd><kwd>therapeutics</kwd><kwd>antivirals</kwd><kwd>monoclonal</kwd><kwd>polyclonal</kwd><kwd>antibodies</kwd><kwd>vaccines</kwd><kwd>viruses</kwd><kwd>respiratory infections</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000074 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000074 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:4918159
|texte= Development of Medical Countermeasures to Middle East Respiratory Syndrome Coronavirus
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:27191188" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |